New target identified for CNS drug development

Researchers at the University of Kentucky have discovered that a
small molecule, called withaferin A, can simultaneously target two of the key proteins implicated in reactive gliosis, a potentially destructive
biological processes seen in ALS and other neurodegenerative diseases, which makes it a promising therapeutic target for further development.

Click here to read more.

Share this: